Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Boehringer Ingelheim
Moodys
AstraZeneca
McKesson

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Glecaprevir; pibrentasvir - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for glecaprevir; pibrentasvir and what is the scope of freedom to operate?

Glecaprevir; pibrentasvir is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Glecaprevir; pibrentasvir has three hundred and eighty-five patent family members in forty-four countries.

One supplier is listed for this compound.

Summary for glecaprevir; pibrentasvir
International Patents:385
US Patents:7
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 15
DailyMed Link:glecaprevir; pibrentasvir at DailyMed
Recent Clinical Trials for glecaprevir; pibrentasvir

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 2
AbbViePhase 2
Kirby InstituteN/A

See all glecaprevir; pibrentasvir clinical trials

US Patents and Regulatory Information for glecaprevir; pibrentasvir

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Abbvie Inc MAVYRET glecaprevir; pibrentasvir TABLET;ORAL 209394-001 Aug 3, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for glecaprevir; pibrentasvir

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2618831 122017000076 Germany   Start Trial PRODUCT NAME: GLECAPREVIR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/17/1213 20170726
2692346 C20170036 00243 Estonia   Start Trial PRODUCT NAME: PIBRENTASVIIR;REG NO/DATE: EU/1/17/1213 28.07.2017
2618831 2017C/041 Belgium   Start Trial PRODUCT NAME: GLECAPREVIR OU UN SEL OU ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1213 20170728
2618831 2017056 Norway   Start Trial PRODUCT NAME: GLEKAPREVIR ELLER ET; REG. NO/DATE: EU/1/17/1213 20170807
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Boehringer Ingelheim
Dow
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.